David M. Berman Sells 22,532 Shares of Immunocore (NASDAQ:IMCR) Stock

Key Points

• David Berman, an insider at Immunocore, sold 22,532 shares at an average price of $35.67, totaling approximately $803,716.
• Immunocore's stock price declined by 1.8% to $33.81, with a market capitalization of $1.70 billion.
• The company reported a 30% year-over-year revenue increase, reaching $130.65 million and beating analyst estimates.

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Get Free Report) insider David M. Berman sold 22,532 shares of the business's stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $35.67, for a total transaction of $803,716.44. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Immunocore Price Performance

IMCR stock traded up $0.44 during midday trading on Friday, reaching $33.86. The company had a trading volume of 14,903 shares, compared to its average volume of 330,310. The company has a debt-to-equity ratio of 1.01, a current ratio of 5.89 and a quick ratio of 5.86. Immunocore Holdings PLC Sponsored ADR has a 1 year low of $23.15 and a 1 year high of $39.33. The company has a market capitalization of $1.71 billion, a P/E ratio of -84.64 and a beta of 0.77. The firm has a 50-day moving average price of $33.98 and a 200-day moving average price of $31.88.

Immunocore (NASDAQ:IMCR - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.01. The firm had revenue of $130.65 million during the quarter, compared to analyst estimates of $122.96 million. Immunocore had a negative net margin of 5.70% and a negative return on equity of 5.40%. The business's quarterly revenue was up 30.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.23) EPS. On average, research analysts anticipate that Immunocore Holdings PLC Sponsored ADR will post -0.94 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Jefferies Financial Group assumed coverage on shares of Immunocore in a report on Monday, August 25th. They issued a "buy" rating and a $48.00 price objective for the company. Wall Street Zen lowered shares of Immunocore from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Zacks Research lowered shares of Immunocore from a "strong-buy" rating to a "hold" rating in a report on Thursday, September 4th. Guggenheim assumed coverage on shares of Immunocore in a report on Thursday. They set a "neutral" rating for the company. Finally, HC Wainwright reiterated a "buy" rating and set a $100.00 price target on shares of Immunocore in a report on Monday, June 2nd. Six investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $56.89.

Institutional Trading of Immunocore

A number of hedge funds and other institutional investors have recently modified their holdings of the business. GF Fund Management CO. LTD. purchased a new stake in Immunocore during the 4th quarter valued at about $25,000. Caitong International Asset Management Co. Ltd lifted its stake in Immunocore by 4,696.3% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 1,295 shares of the company's stock valued at $41,000 after acquiring an additional 1,268 shares during the period. Elevation Point Wealth Partners LLC bought a new position in Immunocore during the 2nd quarter valued at about $42,000. Osaic Holdings Inc. lifted its stake in Immunocore by 117.4% during the 2nd quarter. Osaic Holdings Inc. now owns 3,148 shares of the company's stock valued at $97,000 after acquiring an additional 1,700 shares during the period. Finally, State of Tennessee Department of Treasury bought a new position in Immunocore during the 2nd quarter valued at about $132,000. 84.50% of the stock is owned by hedge funds and other institutional investors.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.